Looking for breakthrough ideas for innovation challenges? Try Patsnap Eureka!

Application of KRAS (kirsten ratsarcoma viral oncogene) serving as biomarker in pancreatic cancer

A technology for pancreatic cancer and uses, applied in the field of KRAS as a biomarker in pancreatic cancer, can solve problems to be studied and so on

Inactive Publication Date: 2017-09-15
SHANGHAI CHANGHAI HOSPITAL
View PDF4 Cites 1 Cited by
  • Summary
  • Abstract
  • Description
  • Claims
  • Application Information

AI Technical Summary

Problems solved by technology

Despite the above-mentioned research reports, there are still many aspects to be studied in the clinical application of cfDNA in resectable pancreatic cancer.

Method used

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
View more

Image

Smart Image Click on the blue labels to locate them in the text.
Viewing Examples
Smart Image
  • Application of KRAS (kirsten ratsarcoma viral oncogene) serving as biomarker in pancreatic cancer
  • Application of KRAS (kirsten ratsarcoma viral oncogene) serving as biomarker in pancreatic cancer
  • Application of KRAS (kirsten ratsarcoma viral oncogene) serving as biomarker in pancreatic cancer

Examples

Experimental program
Comparison scheme
Effect test

Embodiment 1

[0044] 1. Sample Collection

[0045]Preoperative venous blood was collected using ethylenediaminetetraacetic acid tubes (Vacutainer blood collection tubes, BD Company, USA), and the samples were sent to Ankeji Biotechnology Co., Ltd. (Shanghai, China) at room temperature for plasma separation. All 85 patients underwent 10ml whole blood sample collection. Blood samples for plasma and white blood cell (WBC) samples were drawn on the day of surgery. The results of cfDNA sequencing are not provided to patients, and treatment decisions are not made based on cfDNA results.

[0046] 2. Extraction of cfDNA and genomic DNA

[0047] Peripheral blood (10 ml per sample) was centrifuged at 4° C., 1600 g, for 10 minutes. Plasma and buffy coat (white blood cell layer) were collected and stored at -70°C. cfDNA was extracted from 3-5 ml plasma using the QIAamp Circulating Nucleic Acid Kit (Qiagen). gDNA (genomicDNA) was extracted from white blood cells using the QIAamp DNA Blood Maxi kit ...

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to View More

PUM

No PUM Login to View More

Abstract

The invention relates to the technical field of biology, in particular to application of KRAS (kirsten ratsarcoma viral oncogene) serving as a biomarker in pancreatic cancer and provides application of a substance for detecting G12V mutation in KRAS gene or active fragments thereof to preparation of a kit used for assessment of pancreatic cancer treatment effects and / or judgment of pancreatic cancer prognosis. According to discovery of remarkable correlation between KRAS mutation in pre-operation cfDNA and shortening of overall survival and progression-free survival, a prognosis value of KRAS cfDNA assessment is revealed, and a method of how to provide information for clinical treatment of patients suffering from the pancreatic cancer on the basis of cfDNA biomarker detection assistance is founded, and accordingly individual treatment of the pancreatic cancer can be promoted.

Description

technical field [0001] The invention relates to the field of biotechnology, in particular to the use of KRAS as a biomarker in pancreatic cancer. Background technique [0002] Pancreatic cancer is one of the tumors with the lowest patient survival rate, with a 5-year survival rate of less than 5%. Pancreatic cancer is thought to arise from somatic mutations accumulated over many years, with typical clinical manifestations in later stages of the disease. Pancreatic cancer patients are often underserved, largely because of limited knowledge of the somatic mutations that drive the disease process, often unable to accurately characterize pancreatic cancer prior to treatment. In the course of the disease, the identification of biomarkers can obtain the patient's prognosis information earlier, which can greatly improve the treatment method and monitor the condition of pancreatic cancer patients. [0003] Cell-free DNA (cfDNA) sequencing has proven to be a feasible and sensitive ...

Claims

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to View More

Application Information

Patent Timeline
no application Login to View More
Patent Type & Authority Applications(China)
IPC IPC(8): C12Q1/68
CPCC12Q1/6886C12Q2600/118C12Q2600/156
Inventor 金钢郭世伟宋博
Owner SHANGHAI CHANGHAI HOSPITAL
Who we serve
  • R&D Engineer
  • R&D Manager
  • IP Professional
Why Patsnap Eureka
  • Industry Leading Data Capabilities
  • Powerful AI technology
  • Patent DNA Extraction
Social media
Patsnap Eureka Blog
Learn More
PatSnap group products

Browse by: Latest US Patents, China's latest patents, Technical Efficacy Thesaurus, Application Domain, Technology Topic, Popular Technical Reports.

© 2024 PatSnap. All rights reserved.Legal|Privacy policy|Modern Slavery Act Transparency Statement|Sitemap|About US| Contact US: help@patsnap.com